---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-092279"
form_type: "8-K"
ticker: "NAMS"
cik: "0001936258"
company_name: "NewAmsterdam Pharma Co N.V."
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:55:20.316513+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# NewAmsterdam reports positive Phase 3 BROOKLYN data; Q2 net loss $39M

## Summary
- Phase 3 BROOKLYN met primary endpoint: LS mean LDL-C reduction 36.3% at day 84 (p<0.0001), sustained at day 365 (-41.5%); safety comparable to placebo.
- US composition of matter patent issued for obicetrapib, extending IP protection to July 2043.
- Cash $430.7M as of June 30, 2024 (up from $340.5M at Dec 31, 2023).
- Q2 net loss $39.0M ($0.41 diluted EPS) vs $38.3M ($0.47) year ago; revenue $2.3M (vs $1.7M).
- Topline data for Phase 3 BROADWAY expected Q4 2024; Phase 3 TANDEM enrollment completed, topline Q1 2025.

## SEC filing metadata
- accession: 0000950170-24-092279
- form_type: 8-K
- ticker: NAMS
- cik: 0001936258
- company_name: NewAmsterdam Pharma Co N.V.
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1936258/000095017024092279/0000950170-24-092279-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1936258/000095017024092279/nams-20240807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-092279
- JSON: https://secwatch.observer/filing/0000950170-24-092279.json
- Plain text: https://secwatch.observer/filing/0000950170-24-092279.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.